UPDATE: Barclays Starts Jazz Pharmaceuticals (JAZZ) at Overweight; Use Share Weakness as Opportunity
Tweet Send to a FriendGet Alerts JAZZ Hot Sheet
Price: $63.00 +2.39%
Rating Summary:
16 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 21 | Down: 24 | New: 29
Rating Summary:
16 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 21 | Down: 24 | New: 29
Trade JAZZ Now!
(Updated - June 21, 2012 3:38 PM EDT)
Barclays initiates coverage on Jazz Pharmaceuticals (NASDAQ: JAZZ) with an Overweight. PT $60.00.
Analyst, Douglas D. Tsao, feels that despite some possible pressure down the road from generic companies, Jazz Pharma offers one of the best options for Specialty Pharma. Tsao cites the current share price, which he feels under-appreciates the cohesiveness of the Xyrem franchise.
Bears think a generic may be available as soon as 2015, but Tsao thinks it will be pushed back closer to 2018. FY12 EPS estimate moved to $4.70 and FY13 to $5.58.
For an analyst ratings summary and ratings history on Jazz Pharmaceuticals click here. For more ratings news on Jazz Pharmaceuticals click here.
Shares of Jazz Pharmaceuticals closed at $46.03 yesterday, with a 52 week range of $29.21-$54.50.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Barclays initiates coverage on Jazz Pharmaceuticals (NASDAQ: JAZZ) with an Overweight. PT $60.00.
Analyst, Douglas D. Tsao, feels that despite some possible pressure down the road from generic companies, Jazz Pharma offers one of the best options for Specialty Pharma. Tsao cites the current share price, which he feels under-appreciates the cohesiveness of the Xyrem franchise.
Bears think a generic may be available as soon as 2015, but Tsao thinks it will be pushed back closer to 2018. FY12 EPS estimate moved to $4.70 and FY13 to $5.58.
For an analyst ratings summary and ratings history on Jazz Pharmaceuticals click here. For more ratings news on Jazz Pharmaceuticals click here.
Shares of Jazz Pharmaceuticals closed at $46.03 yesterday, with a 52 week range of $29.21-$54.50.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Jazz Pharma (JAZZ) Could Be Takeout Target
- MKM Partners Lifts PT on KB Home (KBH) After Management Meetings
- Topeka Capital Starts CEVA Inc. (CEVA) at Buy
Create E-mail Alert Related Categories
Analyst EPS Change, New CoverageRelated Entities
Barclays
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
